Nancy Hill Net Worth

The estimated Net Worth of Nancy Louise Hill is at least $154 Thousand dollars as of 19 January 2021. Ms. Hill owns over 25,000 units of Adaptive Biotechnologies stock worth over $153,650 and over the last 5 years she sold ADPT stock worth over $0. In addition, she makes $0 as Senior Vice President - Operations at Adaptive Biotechnologies.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Hill ADPT stock SEC Form 4 insiders trading

Nancy has made over 7 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 25,000 units of ADPT stock worth $95,250 on 19 January 2021.

The largest trade she's ever made was exercising 57,000 units of Adaptive Biotechnologies stock on 22 December 2020 worth over $47,880. On average, Nancy trades about 20,375 units every 26 days since 2020. As of 19 January 2021 she still owns at least 35,000 units of Adaptive Biotechnologies stock.

You can see the complete history of Ms. Hill stock trades at the bottom of the page.

Nancy Hill biography

Nancy Louise Hill serves as Senior Vice President - Operations of the Company. Prior to joining us, Ms. Hill served as Vice President, Sales and Marketing and member of the executive team at Spiration, Inc. from 2007 to 2013. Ms. Hill also served at Berlex Oncology as Vice President, Marketing from 2004 to 2005 and as Marketing Director from 2002 to 2004. Prior to that time, Ms. Hill held various positions of increasing responsibility on the new products and oncology commercial teams at Immunex Corporation and Amgen Inc. Ms. Hill holds an MBA from the Kellogg School of Management at Northwestern University and a BA in Business Administration from the University of Washington.

How old is Nancy Hill?

Nancy Hill is 56, she's been the Senior Vice President - Operations of Adaptive Biotechnologies since 2018. There are 4 older and 20 younger executives at Adaptive Biotechnologies. The oldest executive at Adaptive Biotechnologies Corporation is Peter Neupert, 64, who is the Lead Independent Director.

What's Nancy Hill's mailing address?

Nancy's mailing address filed with the SEC is C/O ADAPTIVE BIOTECHNOLOGIES CORP., SUITE 200, SEATTLE, WA, 98102.

Insiders trading at Adaptive Biotechnologies

Over the last 5 years, insiders at Adaptive Biotechnologies have traded over $685,617,014 worth of Adaptive Biotechnologies stock. The most active insiders traders include Global Investors Lp Viking ..., Global Performance Llc Viki..., and Kevin T Conroy. On average, Adaptive Biotechnologies executives and independent directors trade stock every 6 days with the average trade being worth of $368,167. The most recent stock trade was executed by Stacy L Taylor on 22 August 2024, trading 26,922 units of ADPT stock currently worth $121,149.

What does Adaptive Biotechnologies do?

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Complete history of Ms. Hill stock trades at Adaptive Biotechnologies

Adaptive Biotechnologies executives and stock owners

Adaptive Biotechnologies executives and other stock owners filed with the SEC include:

• Lance Baldo,
  Chief Medical Officer
• Chad Robins,
  Executive Chairman, Chief Executive Officer, Co-Founder
• Harlan Robins,
  Co-Founder, Chief Scientific Officer
• Julie Rubinstein,
  President
• Chad M. Robins M.B.A, M.B.A.,
  Co-Founder, CEO & Chairman
• Michelle Griffin,
  Independent Director
• Kevin Conroy,
  Independent Director
• Dr. Harlan S. Robins Ph.D.,
  Co-Founder & Chief Scientific Officer
• Julie Rubinstein,
  Pres
• Chad M. Cohen CPA,
  Chief Financial Officer
• Dr. Mark Adams,
  COO & CTO
• Peter Neupert,
  Lead Independent Director
• Eric Dobmeier,
  Independent Director
• Michael Pellini,
  Independent Director
• Robert Hershberg,
  Independent Director
• David Goel,
  Independent Director
• Sean Nolan,
  Chief Technical Officer
• Mark Adams,
  Chief Technical Officer
• Charles Snag,
  Senior Vice President - Clinical Diagnostics
• Jyoti Palaniappan,
  Senior Vice President - Clinical Diagnostics immunoSEQ Dx
• Nancy Hill,
  Senior Vice President - Operations
• Sharon Benzeno,
  Senior Vice President - Drug Recovery
• Stacy Taylor,
  Senior Vice President, General Counsel
• Francis Lo,
  Chief People Officer
• Chad Cohen,
  Chief Financial Officer
• Francis T. Lo,
  Chief People Officer
• Stacy L. Taylor,
  Sr. VP & Gen. Counsel
• Karina Calzadilla,
  VP of Investor Relations
• Kyle Piskel,
  Principal Accounting Officer
• Christopher Carlson Ph.D.,
  Founder
• Charles Sang,
  SVP, External Affairs
• Global Investors Lpviking G...,
  
• Andris A Zoltners,
  Director
• David E.Matrix Capital Mana...,
  
• Global Performance Llc Viki...,
  
• Susan Bobulsky,
  Chief Commercial Officer, MRD
• Katey Einterz Owen,
  Director
• Leslie Trigg,
  Director
• Henning Thorsen,
  SVP, Commercial Operations
• Kyle Piskel,
  Chief Financial Officer
• Nitin Sood,
  Chief Commercial Officer, MRD
• Tycho Peterson,
  Chief Financial Officer